<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254513</url>
  </required_header>
  <id_info>
    <org_study_id>GERICO10/0910 (GetugP03)</org_study_id>
    <nct_id>NCT01254513</nct_id>
  </id_info>
  <brief_title>Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients</brief_title>
  <acronym>GERICO10</acronym>
  <official_title>Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (&gt;=75), &quot;Vulnerable&quot; or &quot;Frail&quot; , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the feasibility of two different chemotherapy
      protocols with adjusted doses for patients aged 75 and over who often have medical problems
      other than prostate cancer. Patient will receive Docetaxel either every 3 weeks or weekly. In
      both cases, chemotherapy is combined with prednisone. The protocol will be considered
      feasible when patient will receive 6 cycles of chemotherapy (1 cycle = 3 weeks).

      Additionally to this primary objective, efficacy will also be evaluated for both protocols as
      well as tolerance to treatment, quality of life and evolution of geriatric data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard management of castration-resistant metastatic prostate cancer is represented by
      chemotherapy with Docetaxel 75 mg/m² every 3 weeks combined with Prednisone since a
      symptomatic and overall survival benefit was demonstrated.

      Although this benefit is independent of age in the study by Tannock (cut-off:69), it does not
      seem possible to extrapolate these results, obtained in a selected population, to the
      majority of patients we encounter in daily practice, &gt;= 75 years old and / or unfit.

      Retrospective studies have shown that chemotherapy was feasible, at standard or adapted doses
      in an unselected elderly population with good results in terms of tolerance and efficacy over
      symptoms.

      Our study aims to evaluate prospectively the feasibility of a chemotherapy with
      Docetaxel/Prednisone administered every 3 weeks (60 mg / m² at D1C1 then 70 mg / m² at D1 for
      subsequent cycles if tolerance is good) or weekly (35mg / m² at D1 and D8 with Day 1 = Day
      21) to patients &gt;= 75 years old, evaluated by comprehensive geriatric assessment, belonging
      to group 2 &quot;vulnerable&quot; or to group 3 &quot;frail&quot; of the classification proposed by the
      International Society of Geriatric Oncology (SIOG).

      Feasibility is defined as the possibility for a patient to receive 6 cycles of chemotherapy
      without withdrawal. Reasons for study withdrawal were defined by the GERICO Group and are the
      followings:

        -  stop or delay of chemotherapy &gt; 2 weeks

        -  Necessity to reduce the dose of chemotherapy &gt; 25 %

        -  febrile neutropenia or non-haematological grade 3 toxicity (except alopecia) according
           to NCI-CTCAE V4.0.

        -  Geriatric criterion (Activity of Daily Living (ADL) decrease &gt;= 2 points)

      The statistical methodology used is a double randomized phase II after stratification
      according to the SIOG criteria, based on a Simon Optimum plan.

      A pharmacokinetic / pharmacodynamic study is associated to our project, based on a method of
      population pharmacokinetic. The aim is to highlight predictors of the haematological
      tolerance of this chemotherapy by evaluating clinical, geriatric and biological parameters.

      The results of this study will support the terms of prescription of chemotherapy, in patients
      aged 75 and over, classified as &quot;vulnerable&quot; or &quot;frail&quot; regarding SIOG criteria, with defined
      geriatric assessment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of 2 different protocols of Docetaxel chemotherapy</measure>
    <time_frame>Up to 18 weeks (6 cycles of chemotherapy)</time_frame>
    <description>Main criteria is the rate of patients receiving 6 cycles of treatment without experiencing any of the following criteria:
Stop or delay of chemotherapy &gt; 2 weeks
Necessity to reduce the dose of chemotherapy &gt; 25 %
Febrile neutropenia or non-haematological grade 3 toxicity (except alopecia)according to NCI-CTCAE V4.0
Geriatric criterion ( ADL decrease &gt;= 2 points)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization until death for any cause or last follow-up news (censored data)</time_frame>
    <description>Overall Survival is defined as the time from randomization until death for any cause or last follow-up news (censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric evaluation</measure>
    <time_frame>At baseline, D1 of Cycle 1 and Cycle 4, at the end of treatment and at follow-up visits</time_frame>
    <description>The impact of the chemotherapy will be evaluated on Comprehensive Geriatric Assessment :
Test de screening G8
Cumulative Illness Rating Scale(CIRSG)
Folstein Mini Mental State (MMS)
Activity of Daily Living (ADL)
Instrumental Activity of Daily Living (IADL)
Geriatric Depression Scale (GDS)
Mini Nutritionnal Assessment (MNA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits</time_frame>
    <description>Tolerance and safety will be assessed through recording of adverse events using NCI-CTCAE toxicity classification V4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At baseline, D1 of the Cycle 4, at the end of the treatment and at the follow-up visits</time_frame>
    <description>The impact of the chemotherapy is evaluated on the European Organisation for Research and Treatment of Cancer (EORTC) Quality Of Life - Questionnaire - QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs measurement</measure>
    <time_frame>At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits</time_frame>
    <description>Tolerance and safety will be assessed through vital signs measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) measurements</measure>
    <time_frame>At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits</time_frame>
    <description>Efficacy will be assessed through monitoring PSA values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A - Docetaxel every 3 weeks + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks
Prednisone 10 mg/day continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Docetaxel weekly + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)
Prednisone 10 mg/day continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel every 3 weeks + Prednisone</intervention_name>
    <description>Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks
Prednisone 10 mg/day continuously</description>
    <arm_group_label>Arm A - Docetaxel every 3 weeks + Prednisone</arm_group_label>
    <other_name>TAXOTERE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel weekly+ Prednisone</intervention_name>
    <description>Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)
Prednisone 10 mg/day continuously</description>
    <arm_group_label>Arm A - Docetaxel every 3 weeks + Prednisone</arm_group_label>
    <arm_group_label>Arm B - Docetaxel weekly + Prednisone</arm_group_label>
    <other_name>TAXOTERE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 75

          -  Histologically proven prostate adenocarcinoma

          -  Metastatic disease, not pre-treated with chemotherapy refractory to castration

          -  Hormone refractory prostate cancer is defined as follows:

               -  Patients with documented testosterone castration (&lt;0.50 ng / ml)

               -  Patient who received prior hormonal therapy (either orchidectomy or Luteinizing
                  hormone-releasing hormone (LHRH) agonist alone or combined with an anti-androgen)

               -  Patients should continue primary androgen suppression by LHRH agonist (in case of
                  non-surgical castration)

               -  For patients treated with anti-androgens prior to inclusion, a wash-out period is
                  required (4 weeks for flutamide and nilutamide, 6 weeks for other products) as
                  well as measured progression after anti-androgen discontinuation.

          -  Progressive disease under hormonotherapy, with progression defined by

        Increase of PSA level (two consecutive increases of PSA compared to baseline with a minimum
        of one week between both measurements)

        OR emergence of a new lesion

        OR measurable progressive disease (increase of a previous measurable lesion &gt;= 25% in cross
        section)

        OR progressive bone metastases (defined only by the appearance of a new lesion on bone
        scan)

        OR progressive symptoms (defined as cancer pain Grade 2 according to the NCI-CTC V4.0,
        despite level 2 analgesics intake).

          -  Patients of Groups 2 and 3 [ &quot;vulnerable&quot; and &quot;frail&quot;] of SIOG classification

          -  WHO Performance Status (PS) &gt;= 3

          -  PSA &gt;= 5 ng / ml

          -  Neutrophils &gt;= 2.109 /L

          -  Platelets &gt;= 100.109/L

          -  Haemoglobin ≥ 9 g/dl

          -  Bilirubin and SGOT / SGPT &lt;1.5 x ULN (&lt;= 2.5 x ULN if hepatic metastasis)

          -  creatinine &lt;= 2.5 x ULN

          -  In case of previous palliative or analgesic radiotherapy, a minimum of 14 days must
             have elapsed between end of radiotherapy and inclusion into the study

          -  Previous treatment with bisphosphonates should be continued without change during the
             study treatment and can not be initiated either within 28 days prior to study entry or
             during the study

          -  Signed informed consent by patients, according to local regulations

        Exclusion Criteria:

          -  &quot;healthy&quot; or &quot;terminal illness&quot; Groups according to the recommendations of
             International Society of Geriatric Oncology (SIOG)

          -  Concomitant or previous malignancy within 5 years prior the study (except basal or
             squamous in situ cell skin carcinoma)

          -  Presence of brain metastasis symptoms

          -  Prior treatment by intravenous radiopharmaceutical agent (e.g. Strontium 89, Samarium
             lexidronam) within 2 months before study entry

          -  Initiation of a bisphosphonate therapy within 28 days prior to randomisation

          -  Any concomitant anticancer treatment (radiotherapy, radiopharmaceutical agent,
             chemotherapy)

          -  Patients with uncontrolled infection

          -  Patients with peripheral neuropathy of grade&gt; 1

          -  Patients medically unstable (e.g. unstable diabetes, uncontrolled hypertension or
             decompensated heart failure or myocardial infarct within 3 months)

          -  Gastro duodenal active ulcer

          -  Hypersensitivity to study drugs

          -  Treatment with any experimental drug within 30 days prior to or during the study

          -  Psychological, familial, sociological or geographical location conditions which do not
             allow medical monitoring and compliance with study protocol.

          -  Patients protected by the law or patients placed under protective supervision of
             adults
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loic Mourey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Orsini</last_name>
    <phone>+33.1.71.93.67.07</phone>
    <email>c-orsini@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe HOUYAU, Dr</last_name>
      <email>philippe.houyau@claude-bernard-albi.com</email>
    </contact>
    <investigator>
      <last_name>Philippe HOUYAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Annemasse-Bonneville</name>
      <address>
        <city>Ambilly</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol ALLIOT</last_name>
      <phone>04 50 87 40 37</phone>
      <email>calliot@chi-annemasse-bonneville.fr</email>
    </contact>
    <investigator>
      <last_name>Carol ALLIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie ABADIE</last_name>
      <email>sophie.abadie-lacourtoisie@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie ABADIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles-Emmanuel GEFFROY</last_name>
      <phone>02 54 55 63 95</phone>
      <email>cegeffroy@ch-blois.fr</email>
    </contact>
    <investigator>
      <last_name>Charles-Emmanuel GEFFROY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine HOUEDE, Dr</last_name>
      <email>houede@bergonie.org</email>
    </contact>
    <investigator>
      <last_name>Nadine HOUEDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel SEVIN, Dr</last_name>
      <email>e.sevin@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel SEVIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne SARDA</last_name>
      <email>c-sarda@chic-cm.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne SARDA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chambery</name>
      <address>
        <city>Chambery</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armelle DUFRESNES, Dr</last_name>
      <email>a.dufresne@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Armelle DUFRESNES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakim MAHAMMEDI</last_name>
      <phone>04 73 27 80 80</phone>
      <email>hakim.mahammedi@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Hakim MAHAMMEDI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François BERDAH</last_name>
    </contact>
    <investigator>
      <last_name>Jean-françois BERDAH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank PRIOU, Dr</last_name>
      <email>frank.priou@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Frank Priou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Levallois-perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel VANNETZEL, Dr</last_name>
      <email>jmvannetzel@i-o-h.org</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel VANNETZEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armelle CATY</last_name>
    </contact>
    <investigator>
      <last_name>Armelle Caty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe DESAUW</last_name>
      <email>desauw.christophe@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Christophe DESAUW</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON</last_name>
    </contact>
    <investigator>
      <last_name>Aude FLECHON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaëlle GRAVIS-MESCAM, Dr</last_name>
      <email>gravisg@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Gwenaëlle GRAVIS-MESCAM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mounira EL DEMERY</last_name>
      <phone>04 66 68 43 77</phone>
      <email>mounia.eldemery@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Mounira EL DEMERY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chr Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme MEUNIER, Dr</last_name>
      <email>jerome.meunier@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme Meunier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie/Claudius Regaud</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe BEUZEBOC</last_name>
    </contact>
    <investigator>
      <last_name>Philippe BEUZEBOC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claire FALANDRY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Region D'Annecy</name>
      <address>
        <city>Pringy Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia STEFANI, Dr</last_name>
      <email>lstefani@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Laetitia STEFANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Périgueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent CANY</last_name>
      <phone>05 53 02 13 32</phone>
      <email>l.cany@oncoradio24.com</email>
    </contact>
    <investigator>
      <last_name>Laurent CANY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Centre Rene Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain GOUPIL, Dr</last_name>
      <email>alain.goupil@curie.net</email>
    </contact>
    <investigator>
      <last_name>Alain GOUPIL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ico - Centre Rene Gauducheau</name>
      <address>
        <city>Saint-herblain Cedex</city>
        <zip>44885</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS, Dr</last_name>
      <email>e-bompas@nantes.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle BOMPAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth CAROLA</last_name>
      <email>elisabeth.carola@ch-senlis.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth CAROLA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian BOREL, Dr</last_name>
      <email>cborel@strasbourg.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Borel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon-les-bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khoutir MAHOUR BACHA</last_name>
      <email>k-mahour@ch-hopitauxduleman.fr</email>
    </contact>
    <investigator>
      <last_name>Khoutir MAHOUR BACHA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc MOUREY</last_name>
      <phone>05 61 42 41 74</phone>
      <email>loic.mourey@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Loic Mourey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Du Parc</name>
      <address>
        <city>Toulouse</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor LATORZEFF, Dr</last_name>
      <email>i.latorzeff@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Igor LATORZEFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean du Languedoc</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne SUC</last_name>
      <email>esucsjl@club-internet.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne SUC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Igor LATORZEFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Prostate cancer</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>Vulnerable and Frail (SIOG classification)</keyword>
  <keyword>castration-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

